Central aminopeptidase and serotonin system activities: Possible relationship

Čičin‐Šain, Lipa; Šimaga, Šumski; Froebe, Ana; Abramić, Marija

doi:10.1016/j.npep.2008.04.007

Cited by 8 publications

(4 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1). Based on DAVID, all genes included in heat map I [Anikster et al, 2002;Iwamoto et al, 2004;Millar et al, 2005], heat map III [Labrada et al, 2002;Gardner and Ghorpade, 2003;Maisel et al, 2007;Sakamoto et al, 2007] and heat map IV [Jentsch, 1992;Zhang et al, 2004;Beasley et al, 2005;Wu, 2006;Han et al, 2007;Cicin-Sain et al, 2008;Simmen et al, 2008;Wegner et al, 2008;Le-Niculescu et al, 2009] were enriched significantly in various brain tissues (P I < 0.03; P III < 0.02; P IV < 0.01), while all genes included in heat map II [Spleiss et al, 1998;Ainiala et al, 2004;Hamilton et al, 2004;Millar et al, 2005;Skibinski et al, 2005;Georgieva et al, 2008] were associated significantly with a number of neuro-psychiatric symptoms or syndromes (P II < 0.01) (Fig. 1).…”

Section: Resultsmentioning

confidence: 99%

Interferon stimulated exonuclease gene 20 kDa links psychiatric events to distinct hepatitis C virus responses in human immunodeficiency virus positive patients

Katsounas

Rasimas

Schlaak

et al. 2014

Journal of Medical Virology

View full text Add to dashboard Cite

Hepatitis C Virus (HCV) infection occurs frequently in patients with preexisting mental illness. Treatment for chronic hepatitis C using interferon formulations often increases risk for neuropsychiatric symptoms. Pegylated-Interferon-α (PegIFN-α) remains crucial for attaining sustained virologic response (SVR); however, PegIFN-α based treatment is associated with psychiatric adverse effects, which require dose reduction and/or interruption. This study's main objective was to identify genes induced by PegIFN-α and expressed in the central nervous system and immune system, which could mediate the development of psychiatric toxicity in association with antiviral outcome. Using peripheral blood mononuclear cells from Human Immunodeficiency Virus (HIV)/HCV co-infected donors (N=28), DNA microarray analysis was performed and 21 differentially regulated genes were identified in patients with psychiatric toxicity vs. those without. Using these 21 expression profiles a two-way-ANOVA was performed to select genes based on antiviral outcome and occurrence of neuropsychiatric adverse events. Microarray analysis demonstrated that Interferon-stimulated-exonuclease-gene 20kDa (ISG20) and Interferon-alpha-inducible-protein 27 (IFI27) were the most regulated genes (P<0.05) between three groups that were built by combining antiviral outcome and neuropsychiatric toxicity. Validation by bDNA assay confirmed that ISG20 expression levels were significantly associated with these outcomes (P<0.035). Baseline levels and induction of ISG20 correlated independently with no occurrence of psychiatric adverse events and non-response to therapy (P<0.001). Among the 21 genes that were associated with psychiatric adverse events and 20 Interferon-inducible genes (IFIGs) used as controls, only ISG20 expression was able to link PegIFN-α related neuropsychiatric toxicity to distinct HCV-responses in patients co-infected with HIV and HCV in vivo.

show abstract

Section: Resultsmentioning

confidence: 99%

Interferon stimulated exonuclease gene 20 kDa links psychiatric events to distinct hepatitis C virus responses in human immunodeficiency virus positive patients

Katsounas

Rasimas

Schlaak

et al. 2014

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…37,38 However, no treatments are available that directly degrade Ang II itself. Although DPP III was found to be a cytosolic protein in the brain tissue and to cleave dipeptides from the N termini of substrates, such as Ang II and enkephalins, 39,40 the kinetic details of its hydrolytic activity against Ang II and, to date, its in vivo effects in hypertensive animals have not been well elucidated.…”

Section: Discussionmentioning

confidence: 99%

Novel Therapeutic Role for Dipeptidyl Peptidase III in the Treatment of Hypertension

et al. 2016

View full text Add to dashboard Cite

Abstract-Dipeptidyl peptidase III (DPP III) cleaves dipeptide residues from the N terminus of polypeptides ranging from 3 to 10 amino acids in length and is implicated in pathophysiological processes through the breakdown of certain oligopeptides or their fragments. In this study, we newly identified the biochemical properties of DPP III for angiotensin II (Ang II), which consists of 8 amino acids. DPP III quickly and effectively digested Ang II with K m = 3.7×10 −6 mol/L. In the in vivo experiments, DPP III remarkably reduced blood pressure in Ang II-infused hypertensive mice without alteration of heart rate. DPP III did not affect hemodynamics in noradrenalin-induced hypertensive mice or normotensive mice, suggesting specificity for Ang II. When DPP III was intravenously injected every other day for 4 weeks after Ang II osmotic minipump implantation in mice, Ang II-induced cardiac fibrosis and hypertrophy were significantly attenuated. This DPP III effect was at least similar to that caused by an angiotensin receptor blocker candesartan. Furthermore, administration of DPP III dramatically reduced the increase in urine albumin excretion and kidney injury and inflammation markers caused by Ang II infusion. Both DPP III and candesartan administration showed slight additive inhibition in the albumin excretion. These results reveal a novel potential use of DPP III in the treatment of hypertension and its protective effects on hypertension-sensitive organs, such as the heart and kidneys.

show abstract

“…DPP3 is primarily a cytosolic protein [22,27–30] although some studies suggested a potential membrane localization [31–35]. The peptidase was found to be associated with important physiological and pathological pathways in mammals, with accumulating evidence for its involvement in protein turnover [36,37], oxidative stress [8,33,38–42], pain modulation, carcinogenesis [10,11,18,19], inflammation [8,12–14,27] as well as blood pressure regulation and the renin‐angiotensin system [43–47].…”

Section: Introductionmentioning

confidence: 99%

The emerging role of dipeptidyl peptidase 3 in pathophysiology

et al. 2022

View full text Add to dashboard Cite

Dipeptidyl peptidase 3 (DPP3), a zinc-dependent aminopeptidase, is a highly conserved enzyme among higher animals. The enzyme cleaves dipeptides from the N-terminus of tetra-to decapeptides, thereby taking part in activation as well as degradation of signalling peptides critical in physiological and pathological processes such as blood pressure regulation, nociception, inflammation and cancer. Besides its catalytic activity, DPP3 moonlights as a regulator of the cellular oxidative stress response pathway, e.g., the Keap1-Nrf2 mediated antioxidative response. The enzyme is also recognized as a key modulator of the renin-angiotensin system. Recently, DPP3 has been attracting growing attention within the scientific community, which has significantly augmented our knowledge of its physiological relevance. Herein, we review recent advances in our understanding of the structure and catalytic activity of DPP3, with a focus on attributing its molecular architecture and catalytic mechanism to its wide-ranging biological functions. We further highlight recent intriguing reports that implicate a broader role for DPP3 as a valuable biomarker in cardiovascular and renal pathologies and furthermore discuss its potential as a promising drug target.International Union of Biochemistry and Molecular Biology system of enzyme nomenclature [1]. Generally,

show abstract

Central aminopeptidase and serotonin system activities: Possible relationship

Cited by 8 publications

References 44 publications

Interferon stimulated exonuclease gene 20 kDa links psychiatric events to distinct hepatitis C virus responses in human immunodeficiency virus positive patients

Interferon stimulated exonuclease gene 20 kDa links psychiatric events to distinct hepatitis C virus responses in human immunodeficiency virus positive patients

Novel Therapeutic Role for Dipeptidyl Peptidase III in the Treatment of Hypertension

The emerging role of dipeptidyl peptidase 3 in pathophysiology

Contact Info

Product

Resources

About